HomeCompareALLK vs XYLD

ALLK vs XYLD: Dividend Comparison 2026

ALLK yields 607.72% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALLK wins by $286605.33M in total portfolio value
10 years
ALLK
ALLK
● Live price
607.72%
Share price
$0.33
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$286605.35M
Annual income
$216,519,218,488.39
Full ALLK calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — ALLK vs XYLD

📍 ALLK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALLKXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALLK + XYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALLK pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALLK
Annual income on $10K today (after 15% tax)
$51,656.03/yr
After 10yr DRIP, annual income (after tax)
$184,041,335,715.13/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, ALLK beats the other by $184,041,332,978.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALLK + XYLD for your $10,000?

ALLK: 50%XYLD: 50%
100% XYLD50/50100% ALLK
Portfolio after 10yr
$143302.69M
Annual income
$108,259,610,853.70/yr
Blended yield
75.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ALLK right now

ALLK
Analyst Ratings
5
Buy
5
Hold
1
Sell
Consensus: Buy
Price Target
$109.50
+33172.6% upside vs current
Range: $1.00 — $218.00
Altman Z
-29.6
Piotroski
1/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALLK buys
0
XYLD buys
0
No recent congressional trades found for ALLK or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALLKXYLD
Forward yield607.72%10.98%
Annual dividend / share$2.00$4.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$286605.35M$25.3K
Annual income after 10y$216,519,218,488.39$3,219.02
Total dividends collected$280771.00M$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ALLK vs XYLD ($10,000, DRIP)

YearALLK PortfolioALLK Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$71,472$60,771.80$10,818$1,098.39+$60.7KALLK
2$482,407$405,931.79$11,738$1,222.51+$470.7KALLK
3$3,076,811$2,560,635.83$12,774$1,364.64+$3.06MALLK
4$18,555,598$15,263,410.61$13,944$1,527.86+$18.54MALLK
5$105,882,914$86,028,423.50$15,270$1,715.87+$105.87MALLK
6$572,079,610$458,784,892.67$16,775$1,933.09+$572.06MALLK
7$2,928,751,131$2,316,625,947.86$18,490$2,184.87+$2928.73MALLK
8$14,217,805,100$11,084,041,390.41$20,450$2,477.63+$14217.78MALLK
9$65,501,061,274$50,288,009,817.01$22,697$2,819.19+$65501.04MALLK
10$286,605,354,052$216,519,218,488.39$25,280$3,219.02+$286605.33MALLK

ALLK vs XYLD: Complete Analysis 2026

ALLKStock

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

Full ALLK Calculator →

XYLDETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this ALLK vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALLK vs SCHDALLK vs JEPIALLK vs OALLK vs KOALLK vs MAINALLK vs QYLDALLK vs JEPQALLK vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.